- Home
- MKTW vs OTLK Comparison
MKTW vs OTLK Comparison
Compare MKTW & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MKTW | OTLK |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.7M | 37.5M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | MKTW | OTLK |
|---|---|---|
| Price | $16.90 | $1.22 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $20.00 | $2.50 |
| AVG Volume (30 Days) | 19.4K | ★ 27.0M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 10.20% | N/A |
| EPS Growth | ★ 1183.33 | 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $512,403,000.00 | $8,146,123.00 |
| Revenue This Year | $1.52 | $1,430.98 |
| Revenue Next Year | $4.55 | $173.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.49 | $0.16 |
| 52 Week High | $21.74 | $3.39 |
Technical Indicators
Market Signals| Indicator | MKTW | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 50.69 | 82.83 |
| Support Level | $16.17 | $1.13 |
| Resistance Level | $17.65 | $1.54 |
| Average True Range (ATR) | 0.65 | 0.15 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 50.26 | 86.63 |
Price Performance
Historical ComparisonAbout MKTW MarketWise Inc.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms, including mobile, desktop, and tablets.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.